Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

计划入组 109 人 · 首次发布于 2016 年 8 月 25 日

Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes

计划入组 9 人 · 首次发布于 2018 年 8 月 31 日

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

计划入组 320 人 · 首次发布于 2020 年 6 月 5 日

C213 Microneedle System

drug delivery system

endocannabinoid system activator

Ryder System

United States

GOSHEN HEALTH SYSTEM

United States

MEMORIAL HEALTHCARE SYSTEM

United States

Fractyl Health's Revita System Receives FDA Breakthrough Device Designation for Weight Maintenance After GLP-1 Discontinuation

Fractyl Health's Revita Procedure Shows Promise in Sustained Weight Loss Management

Fractyl Health's Revita Shows Sustained Weight Loss and Improved Blood Sugar in Real-World Setting